Cargando…
The community pharmacy model for colorectal cancer screening: policy insights from Italy
BACKGROUND: Despite its effectiveness, compliance to colorectal cancer (CRC) screening remains low. Different strategies to improve the adherence were identified, such as the involvement of new stakeholders as the community pharmacists. In Italy a recent national project fuelled the development of t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594742/ http://dx.doi.org/10.1093/eurpub/ckac130.111 |
_version_ | 1784815497738452992 |
---|---|
author | Deandrea, S Della Valle, PG Battisti, F Mantellini, P Mantovani, W Narne, E Odone, A Senore, C Brusa, P Calsolaro, R |
author_facet | Deandrea, S Della Valle, PG Battisti, F Mantellini, P Mantovani, W Narne, E Odone, A Senore, C Brusa, P Calsolaro, R |
author_sort | Deandrea, S |
collection | PubMed |
description | BACKGROUND: Despite its effectiveness, compliance to colorectal cancer (CRC) screening remains low. Different strategies to improve the adherence were identified, such as the involvement of new stakeholders as the community pharmacists. In Italy a recent national project fuelled the development of this strategy, scaling-up the collaboration between screening programmes and pharmacies formerly at the local level up to the national level. METHODS: The regional representatives of the CRC screening programmes provided to the National Screening Monitoring Centre the agreements arranged between the Regions/Autonomous provinces and their respective pharmacy owners representatives. The agreement decrees were analysed describing the fecal occult blood test pathway (e.g. kit supply and delivery) and supplementary activities provided by the pharmacies together with the CRC screening kit delivery, such as health promotion ones. RESULTS: Information was received from 18 Regions and Autonomous provinces (86% of the total). Regarding the economic compensation, the amount of money paid for each kit varies a lot, with a range from 0 to 18 EUR. The number of process phases covered by the agreements ranged from a maximum of 16 (out of 18) to a minimum of 0. The processes that were included most often were the supply of the kit, the delivery of the kit, and education/awareness of CRC screening (68.8%), followed by sample transfer to the laboratory, test tube tracing and counselling (62.5%). Among the processes less covered there were the warehouse management and awareness of other healthcare initiatives (12.5%), and only in one case a supplementary agreement on delivery of preparation for intestinal cleansing was included. CONCLUSIONS: The arrangements between pharmacies and CRC screening programmes in Italy are very diverse and unique model is missing. Collaboration between programs and pharmacies is promising and quality standards of the service should be set at international level. KEY MESSAGES: Collaboration between organized colorectal cancer screening programmes and community pharmacies can improve the quality of the service and adherence to screening. Quality standards of the pharmacy service in colorectal cancer screening should be set at international level. |
format | Online Article Text |
id | pubmed-9594742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95947422022-11-22 The community pharmacy model for colorectal cancer screening: policy insights from Italy Deandrea, S Della Valle, PG Battisti, F Mantellini, P Mantovani, W Narne, E Odone, A Senore, C Brusa, P Calsolaro, R Eur J Public Health Poster Walks BACKGROUND: Despite its effectiveness, compliance to colorectal cancer (CRC) screening remains low. Different strategies to improve the adherence were identified, such as the involvement of new stakeholders as the community pharmacists. In Italy a recent national project fuelled the development of this strategy, scaling-up the collaboration between screening programmes and pharmacies formerly at the local level up to the national level. METHODS: The regional representatives of the CRC screening programmes provided to the National Screening Monitoring Centre the agreements arranged between the Regions/Autonomous provinces and their respective pharmacy owners representatives. The agreement decrees were analysed describing the fecal occult blood test pathway (e.g. kit supply and delivery) and supplementary activities provided by the pharmacies together with the CRC screening kit delivery, such as health promotion ones. RESULTS: Information was received from 18 Regions and Autonomous provinces (86% of the total). Regarding the economic compensation, the amount of money paid for each kit varies a lot, with a range from 0 to 18 EUR. The number of process phases covered by the agreements ranged from a maximum of 16 (out of 18) to a minimum of 0. The processes that were included most often were the supply of the kit, the delivery of the kit, and education/awareness of CRC screening (68.8%), followed by sample transfer to the laboratory, test tube tracing and counselling (62.5%). Among the processes less covered there were the warehouse management and awareness of other healthcare initiatives (12.5%), and only in one case a supplementary agreement on delivery of preparation for intestinal cleansing was included. CONCLUSIONS: The arrangements between pharmacies and CRC screening programmes in Italy are very diverse and unique model is missing. Collaboration between programs and pharmacies is promising and quality standards of the service should be set at international level. KEY MESSAGES: Collaboration between organized colorectal cancer screening programmes and community pharmacies can improve the quality of the service and adherence to screening. Quality standards of the pharmacy service in colorectal cancer screening should be set at international level. Oxford University Press 2022-10-25 /pmc/articles/PMC9594742/ http://dx.doi.org/10.1093/eurpub/ckac130.111 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Poster Walks Deandrea, S Della Valle, PG Battisti, F Mantellini, P Mantovani, W Narne, E Odone, A Senore, C Brusa, P Calsolaro, R The community pharmacy model for colorectal cancer screening: policy insights from Italy |
title | The community pharmacy model for colorectal cancer screening: policy insights from Italy |
title_full | The community pharmacy model for colorectal cancer screening: policy insights from Italy |
title_fullStr | The community pharmacy model for colorectal cancer screening: policy insights from Italy |
title_full_unstemmed | The community pharmacy model for colorectal cancer screening: policy insights from Italy |
title_short | The community pharmacy model for colorectal cancer screening: policy insights from Italy |
title_sort | community pharmacy model for colorectal cancer screening: policy insights from italy |
topic | Poster Walks |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594742/ http://dx.doi.org/10.1093/eurpub/ckac130.111 |
work_keys_str_mv | AT deandreas thecommunitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT dellavallepg thecommunitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT battistif thecommunitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT mantellinip thecommunitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT mantovaniw thecommunitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT narnee thecommunitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT odonea thecommunitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT senorec thecommunitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT brusap thecommunitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT calsolaror thecommunitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT deandreas communitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT dellavallepg communitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT battistif communitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT mantellinip communitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT mantovaniw communitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT narnee communitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT odonea communitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT senorec communitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT brusap communitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly AT calsolaror communitypharmacymodelforcolorectalcancerscreeningpolicyinsightsfromitaly |